Number Needed to Treat to Benefit and to Harm for Intravenous Tissue Plasminogen Activator Therapy in the 3- to 4.5-Hour Window: Joint Outcome Table Analysis of the ECASS 3 Trial
Stroke 40:2433-2437,2295, Saver,J.L.,et al, 2009
Hemorrhage After Thrombolytic Therapy for Stroke: The Clinically Relevant Number Needed to Harm
Stroke 38:2279-2283, Saver,J.L., 2007
The Stroke-Thrombolytic Predictive Instrument: A Predictive Instrument for Intravenous Thrombolysis in Acute Ischemic Stroke
Stroke 37:2957-2962,2865, Kent,D.M.,et al, 2006
Can Multivariable Risk-Benefit Profiling Be Used to Select Treatment-Favorable Patients for Thrombolysis in Stroke in the 3- to 6-Hour Time Window?
Stroke 37:2963-2969, Kent,D.M.,et al, 2006
Diagnosis and Treatment of Ischemic Stroke
Am J Med 106:211-221, Alberts,M.J., 1999
DAWN: Thrombectomy Effective Up to 24 Hours after Stroke
Medscape May, Hughes, S., 2017
An Observational Study of Thrombolysis Outcomes in Wake-Up Ischemic Stroke Patients
Stroke 44:427-431, Manawadu, D.,et al, 2013
Elderly Patients are at Higher Risk for Poor Outcomes after Intra-Arterial Therapy
Stroke 43:2356-2361, Chandra, R.V.,et al, 2012
Intravenous thrombolysis in acute ischaemic stroke: a systematic review and meta-analysis to aid decision making in patients over 80 years of age
JNNP 82:712-717, Bhatnagar, P.,et al, 2011
Bleeding Risk Analysis in Stroke Imaging Before ThromboLysis (BRASIL): Pooled Analysis of T2*-Weighted Magnetic Resonance Imaging Data From 570 Patients
Storke 38:2738-2744, Fiehler,J.,et al, 2007
Thrombolysis for Acute Stroke with Special Emphasis on the Very Old:Experience From a Single Dutch Centre
JNNP 77:375-377,288, van Oostenbrugge,R.J.,et al, 2006
Patent Foramen Ovale Management for Secondary Stroke Prevention:State-of-the-Art Appraisal of Current Evidence
Stroke 55:236-247, Sposato,L.A.,et al, 2024
Dual Antiplatelet Treatment up to 72 Hours After Ischemic Stroke
NEJM 389:2413-2424, 2478, Gao,Y.et al, 2023
Drugs Associated with Ischemic Stroke
Stroke 52:e646-e659, Marto, J.P.,et al, 2021
Infection Risks Among Patients with Multiple Sclerosis Treated with Fingolimod, Natalizumab, Rituximab, and Injectable Therapies
JAMA Neurol 77:184-191, Luna, G.,et al, 2020
Antiplatelet and Anticoagulant Risk for Select Spine Interventions:A Retrospective Cohort
Pain Med 21:910-917, Ehsanian,R.,et al, 2020
Should Patients with Ischemic Stroke or Transient Ischemic Attack with Atrial Fibrillation and Microbleeds be Anticoagulated?
Stroke 48:3408-3412, Shoamanesh, A.,et al, 2017
Managing Risk After Intracerebral Hemorrhage in Concomitant Atrial Fibrillation and Cerebral Amyloid Angiopathy
Stroke 47:e190-e192, Stoker, T.B.,et al, 2016
Lithium Therapy in Kleine-Levin Syndrome
Neurol 85:1655-1662, Leu-Semenescu, S.,et al, 2015
Should Statins be Paused or Discontinued After Thrombolysis or Acute Intracerebral Hemorrhage? No!
Stroke 44:1472-1476, Scheitz, J.F.,et al, 2013
Seizure risk with AVM Treatment or Conservative Management
Neurol 79:500-507, Josephson, C.B.,et al, 2012
Statin Use Following Intracerebral Hemorrhage
Arch Neurol 68:573-579, Westover, M.B.,et al, 2011
Treatment of Brain Arteriovenous Malformations
JAMA 306:2011-2019, Beijnum, J.V.,et al, 2011
A New Landscape for Stroke Prevention in Atrial Fibrillation
Stroke 42:3316-3322, Banerjee, A.,et al, 2011
10-Year Stroke Prevention After Successful Carotid Endarterectomy for Asymptomatic Stenosis (ACST-1): A Multicentre Randomised Trial
Lancet 376:1074-1084, Halliday,A.,et al, 2010
Risperidone, Haloperidol, and Placebo in the Treatment of Aggressive Challenging Behaviour in Patients With Intellectual Disability: A Randomised Controlled Trial
Lancet 371:57-63,9, Tyrer,P.,et al, 2008
Quantifying the Risks and Benefits of Natalizumab in Relapsing Multiple Sclerosis
Neurol 68:1524-1528, Dorsey,E.R.,et al, 2007
Warfarin Versus Aspirin for Stroke Prevention in an Elderly Community Population With Atrial Fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): A Randomised Controlled Trial
Lancet 370:493-503,460, Mant,J.,et al, 2007
Adding Aspirin to Clopidogrel After TIA and Ischemic Stroke
Neurol 64:1117-1121, Hankey,G.J. &Eikelboom,J.W., 2005
Identification, Prognosis, and Management of Patients with Carotid Artery Near Occlusion
AJNR 26:2086-2094, Fox,A.J.,et al, 2005
Reanalysis of the Final Results of the European Carotid Surgery Trial
Stroke 34:514-523, Rothwell,P.M.,et al, 2003
Unruptured Intracranial Aneurysms: Natural History, Clinical Outcome, and Risks of Surgical and Endovascular Treatment
Lancet 362:103-110,90, International Study of Unruptured Intracranial Ane, 2003
A Risk Score for Predicting Stroke or Death in Individuals with New-Onset Atrial Fibrillation in the Community
JAMA 290:1049-1056,1093, Wang,T.J.,et al, 2003
Stroke Prevention in Atrial Fibrillation
JAMA 290:1093-1095, Waldo,A.L., 2003
The Risk-Benefit Profile of Commonly Used Herbal Therapies: Ginkgo, St. John's Wort, Genseng, Echinacea, Saw Palmetto, and Kava
Ann Int Med 136:42-53, Ernst,E., 2002
Emergent Use of Anticoagulation for Treatment of Patients with Ischemic Stroke
Stroke 33:856-861, Adams,H.P., 2002
Is There a Neurologist on the Flight?
Neurol 58:1739-1744,1717, Sirven,J.I.,et al, 2002
Hospital and Surgeon Determinants of Carotid Endarterectomy Outcomes
Arch Neurol 59:1877-1881,1866, Feasby,T.E.,et al, 2002
Warfarin Therapy for an Octogenarian who has Atrial Fibrillation
Ann Int Med 134:465-474, Gage,B.F.,et al, 2001
Risk, Causes, and Prevention of Ischaemic Stroke in Elderly Patients with Symptomatic Internal-Carotid-Artery Stenosis
Lancet 357:1154-1160,1142, Alamowitch,S.,et al, 2001
Tinzaparin in Acute Ischaemic Stroke (TAIST):A Randomised Aspirin-Controlled Trial
Lancet 358:702-710,683, Bath,P.M.W.,et al, 2001
Aspirin for the Primary Prevention of Stroke and Other Major Vascular Events
ArchNeurol 57:326-332,306, Hart,R.G.,et al, 2000
Low Molecular-Weight Heparin Versus Aspirin in Patients With Acute Ischaemic Stroke and Atrial Fibrillation: A Double-Blind Randomised Study
Lancet 355:1205-1210, Berge,E.,et al, 2000
Treating Nondementia Illnesses in Patients With Dementia
JAMA 283:3230-3235, Brauner,D.J. et al, 2000
Carotid Endarterectomy, Where Do We Draw The Line?
Stroke 30:1745-1750, Gorelick,P.B., 1999
Heparin in Acute Stroke with Atrial Fibrillation, Clinical Relevance of Very Early Treatment
Arch Neurol 56:1098-1102,1059, Chamorro,A.,et al, 1999
Antithrombotic Therapy to Prevent Stroke in Patients with Atrial Fibrillation:A Meta-Analysis
Ann Int Med 131:492-501,537, Hart,R.G.,et al, 1999
Adverse Events Associated with Disease-Modifying Drugs for Multiple Sclerosis
Neurol 102:e208006, Ng, HS.,et al, 2024
Improving Neurology Clinical Care with Natural Language Processing Tools
Neurol 101:1010-1018, Ge,W.,et al, 2023